Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001732369-26-000008
Filing Date
2026-02-26
Accepted
2026-02-26 16:15:24
Documents
1
Period of Report
2026-02-24

Document Format Files

Seq Description Document Type Size
1 form4-02262026_040216.html 4  
1 form4-02262026_040216.xml 4 6670
  Complete submission text file 0001732369-26-000008.txt   8065
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET WALTHAM MA 02451
Business Address
Seehra Jasbir (Reporting) CIK: 0001732369 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 26688274